Novo Nordisk's Quiet Bet on a Disease That Isn't Obesity
Novo Nordisk just posted positive phase 3 results for an oral sickle cell disease drug, and the rest of the SCD field felt the tremor immediately. The GLP-1 giant is filing for approval later this year, and what it means for patients and competitors is worth your attention.
Imagine you're the most popular kid in school because of one thing: you throw incredible parties. Everyone knows you for it. Now imagine you quietly join the chess team and start winning tournaments. That's basically what Novo Nordisk just did.
The Danish pharma giant, synonymous with GLP-1 blockbusters like Ozempic and Wegovy, just dropped positive phase 2 results for a sickle cell disease drug. And it's not a side project. It's a potential first-in-class oral therapy that could reshape how millions of people manage one of the world's most painful inherited diseases.
A Pill for a Disease That Desperately Needs One
Sickle cell disease (SCD) is a genetic blood disorder that causes red blood cells to twist into rigid, crescent shapes. Those misshapen cells clog blood vessels, triggering episodes of excruciating pain called vaso-occlusive crises (VOCs). Think of it like trying to push crumpled paper through a straw: things jam up, blood flow stops, and the damage compounds over time.
About 7.74 million people worldwide live with SCD, with the vast majority in sub-Saharan Africa. In the U.S., around 100,000 Americans are affected, predominantly Black communities that already face disproportionate barriers to healthcare access. Patients with SCD live roughly 20–25 years less than average, dealing with strokes, organ damage, and chronic pain along the way.
For decades, the standard of care was hydroxyurea, a decades-old drug that helps but doesn't come close to solving the problem. Gene therapies like Vertex and CRISPR's Casgevy arrived in 2023 with curative potential, but they're extraordinarily expensive, logistically complex, and available to only a fraction of patients. Meanwhile, Pfizer pulled its oral therapy Oxbryta off the market in 2024 over safety concerns.
The field has been waiting for something simple, effective, and accessible. Novo thinks it has the answer.
The Drug: Etavopivat Does Something Different
The drug is called etavopivat (also known as NN7535), and its mechanism is genuinely clever. Rather than masking symptoms or editing genes, it activates an enzyme in red blood cells called pyruvate kinase-R (PKR). Think of PKR as the battery pack inside each red blood cell. When it's boosted, the cells produce more energy, hold onto oxygen more tightly, and resist sickling in the first place.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
It's a once-daily pill. That matters enormously in a disease where the alternatives are either old drugs with limited efficacy or gene therapies that require bone marrow extraction, chemotherapy conditioning, and hospital stays.
Novo Nordisk didn't develop etavopivat from scratch. It came through the 2022 acquisition of Forma Therapeutics, a deal that signaled Novo's ambitions beyond metabolic disease long before most people were paying attention.
The HIBISCUS Trial: Both Boxes Checked
The phase 2 portion of the phase 2/3 study, called HIBISCUS, enrolled 60 adolescents and adults (aged 12 and up) with SCD. It was randomized, double-blinded, and ran for 52 weeks, with patients allowed to stay on their existing treatments. This wasn't a lab curiosity; it was a real-world stress test.
Etavopivat met both co-primary endpoints, which is the clinical trial equivalent of acing both the written and practical portions of your driver's test.
First, it reduced the annualized rate of vaso-occlusive crises by approximately 46% versus placebo. These are episodes so painful that patients often end up in emergency rooms. A reduction of this magnitude translates into meaningfully fewer hospital visits, fewer missed days of school or work, and less cumulative organ damage.
The time-to-first-crisis data tells the story even more vividly. Patients on etavopivat went a median of 33.6 weeks before their first VOC. Placebo patients? Just 16.9 weeks. That's roughly double the pain-free window.
Second, hemoglobin response was notable. In the per-protocol population, 46% of etavopivat patients (200 mg dose) achieved a meaningful hemoglobin increase of more than 1 g/dL at week 24, compared to approximately 13% on placebo.
Exploratory analyses also hinted at reduced blood transfusion risk, and the safety profile held steady with what earlier trials had shown. No new red flags.
Why This Matters Beyond the Data
Let's zoom out. Sickle cell disease has historically been one of the most underfunded, under-researched serious genetic diseases in the world. It disproportionately affects communities of color in both the U.S. and globally. These aren't people who can easily access a $2 million gene therapy at a specialized medical center.
An oral pill that works on top of existing treatments? That's a game changer for accessibility. You don't need a bone marrow transplant team. You don't need chemotherapy conditioning. You need a prescription and a glass of water.
Novo Nordisk is preparing to file for regulatory approval in the second half of 2026. The drug already carries Fast Track, Rare Pediatric Disease, and Orphan Drug designations from the FDA, plus Orphan Drug status in the EU. All of those designations grease the wheels for faster review. If things go smoothly, etavopivat could be on the market by 2027.
The Competition Is Watching (and Wincing)
Novo's announcement sent shockwaves through the SCD space. Agios Pharmaceuticals, which is developing its own PKR activator called mitapivat, saw its shares drop 15% in premarket trading on the news. Goldman Sachs analyst Salveen Richter maintained a Neutral rating on Agios but raised the price target to $32 from $28, essentially saying: "You're not dead, but your new neighbor is very large and very well-funded."
The broader SCD treatment landscape is crowded but fragmented. Casgevy and Lyfgenia (bluebird bio's gene therapy) represent the curative end of the spectrum. Pfizer, after absorbing Global Blood Therapeutics, is advancing inclacumab and other pipeline candidates. Editas Medicine has reni-cel in a phase 1/2/3 trial. Beam Therapeutics is pushing base-editing approaches.
But none of them have what etavopivat has: a simple oral formulation, positive phase 2 data from a rigorous trial, and the backing of a company with $30 billion+ in annual revenue. The SCD market is projected to grow from roughly $4 billion today to over $14 billion by 2034, and Novo just planted its flag.
Novo's Bigger Play: Not Just a GLP-1 Company Anymore
This is part of a deliberate, multi-year strategy to diversify beyond obesity and diabetes. Novo Nordisk has been on an acquisition and licensing spree that reads like a shopping list for a completely different company.
In hematology alone, Novo has submitted Mim8 for regulatory approval in hemophilia. It licensed a MASP-3 inhibitor called zaltenibart from Omeros for rare blood and kidney disorders. It acquired Akero Therapeutics for a phase 3 liver disease candidate. It struck deals worth billions with companies like The United Laboratories ($2 billion for a triple receptor agonist), Septerna ($2.2 billion for another triple agonist), Deep Apple Therapeutics ($812 million for oral cardiometabolic drugs), and Replicate Bioscience ($550 million for RNA therapies).
The message is unmistakable: Novo Nordisk is building a rare disease franchise alongside its metabolic empire. Etavopivat is the most advanced piece of that puzzle.
The Bottom Line
The SCD data alone won't transform the stock overnight, but it adds a tangible, near-term catalyst to a stock that's been weighed down by unrelated setbacks (including a disappointing Alzheimer's trial with semaglutide).
For patients, the calculus is simpler. Sickle cell disease has been neglected for too long, and the people who suffer from it deserve better options than what currently exists. A once-daily pill that cuts pain crises by nearly half and meaningfully boosts hemoglobin response rates isn't a cure. But it might be the most practical advance the field has seen in years.
Novo Nordisk built its reputation on making metabolic diseases manageable. Now it's trying to do the same for sickle cell. The phase 2 data suggests it's off to a very strong start.
Funding & Financings4 min read
The $700M Biotech That Got Rejected by Wall Street Is Back for Round Two
Odyssey Therapeutics got rejected by Wall Street in 2025 when it pulled its IPO amid a frozen biotech market. Now it's back with $700 million in venture backing and a new S-1 filing, testing whether the 2026 recovery is real.
